DDK-1 specific siRNA and application thereof in treatment of rheumatoid arthritis

A DKK-1, rheumatoid technology, applied in the direction of DNA / RNA fragments, recombinant DNA technology, gene therapy, etc., can solve the problems of restricting the development of treatment methods and unclear pathogenesis

Active Publication Date: 2010-02-10
PEOPLES HOSPITAL PEKING UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of RA is not clea...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DDK-1 specific siRNA and application thereof in treatment of rheumatoid arthritis
  • DDK-1 specific siRNA and application thereof in treatment of rheumatoid arthritis
  • DDK-1 specific siRNA and application thereof in treatment of rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Screening and identification of siRNA

[0016] Collect the synovial tissue after knee joint replacement in RA patients, isolate and culture synovial fibroblasts, and use the cells after 3 generations for experiment. Spread in a 12-well plate, 5×10 cells per well 4 One, set up multiple holes. After 48 hours, the cells were collected, the total RNA was extracted by Trizol method, and A260 was measured with an ultraviolet spectrophotometer. The relative expression level of DKK-1 uses ΔCt and 2 -ΔΔCt For calculation, GAPD is used as an internal reference. Real-time quantitative PCR uses SYBR from ABI Green PCR Master Mix is ​​operated. ELISA method was used to detect the expression level of DKK-1 in the cell supernatant. The results showed that after the 6 pairs of siRNAs designed were transferred into the cells, they could significantly inhibit the expression of DKK-1, and a pair of siRNAs with high inhibition efficiency was screened, as shown in Figure 1 and ...

Embodiment 2

[0017] Example 2: The effect of siRNA targeting DKK-1 on the proliferation ability of RA-FLS

[0018] Isolate and culture synovial fibroblasts and divide them into two groups, one group is no TNF-α activation group, and the other is TNF-α activation group (10ng / ml). Lipo2000 liposome transfection and chemical synthesis of siRNA were performed at the same time as control. Use unrelated sequence siRNA. Use 96-well plates for transfection, 5×10 cells per well 3 , Set up a complex hole. Collect the cells after 48 hours, 3 The H incorporation method was used to detect the proliferation of fibroblast-like synovial cells. The results showed that the proliferation of FLS in the TNF-α activated group was more obvious, but after transfection of siRNA, the proliferation of FLS in the two groups was significantly inhibited, as shown in Figure 3.

Embodiment 3

[0019] Example 3: The effect of down-regulating the expression of DKK-1 on the secretion of inflammatory factors by RA-FLS

[0020] Use FLS of RA patients after 3 generations, 5×10 4 / Well was inoculated into a 12-well plate, Lipo2000 liposomes were transfected with chemically synthesized siRNA and negative control, and then divided into TNF-α induction (10ng / ml) and no TNF-α groups. Each group was a duplicate well and was detected by ELISA The secretion levels of IL-6, IL-8, MMP2 and MMP9 in FLS supernatant 48h after transfection. The results showed that FLS secreted more inflammatory factors in the TNF-α activated group, but after transfection of siRNA, the secretion of FLS inflammatory factors in the two groups had a significant inhibitory effect. Figure 4, Figure 5, Figure 6 and Figure 7.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention designs a pair of targeting DKK-1 (Dickkopf-related protein-1) specific siRNA (small interfering ribonucleic acid) capable of obviously down-regulating the DKK-1 expression of over-activated synovial fibroblasts in patients with rheumatoid arthritis (RA) and inhibiting the abilities of cell proliferation and inflammatory factor secretion and invasion, thereby attaching great significance to the immunotherapy for RA treatment.

Description

Technical field [0001] This study involves the expression level of DKK-1 in fibroid synovial cells of patients with rheumatoid arthritis, the inhibitory effect of small interfering RNA (siRNA) targeting DKK-1 on cell function, and the pathway of action. Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic disabling arthritis, which accounts for about 0.5-1% of the total population. It is also the main cause of the loss of young and middle-aged labor in my country one. The pathological feature is that a large number of inflammatory cells accumulate and proliferate in the joint synovial tissue, synovial cells and blood vessels, and the proliferated synovial tissue grows to the articular cartilage surface and erode the articular cartilage and secretes a variety of inflammatory factors and enzymes, causing articular cartilage And bone destruction, and finally joint deformity and dysfunction, leading to disability. At present, the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11A61K48/00A61P19/04A61P29/00C12N15/113
Inventor 栗占国王世瑶刘燕鹰
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap